β -escin, which is a mixture of triterpene saponins isolated from of the horse chestnut seeds (Aesculus hippocastanum) has been traditionally attributed with the anti-edematous, anti-inflammatory and venotonic properties. As such, β-escin is an active ingredient of popular vascular anti-inflammatory and anti-edematous drug formulations (Escin®, Reparil®, Venitan®). However, despite the widespread clinical use, the pharmacological mechanisms of β -escin action remains largely unknown. We therefore aimed to determine the molecular basis for therapeutic effectiveness of β-escin using i) human gene expression microarrays covering all the transcriptional activity of endothelial cells, ii) global proteomic analysis providing mechanistic information on β-escin action and iii) broad panel of cellular responses including migration, proliferation, permeability and apoptosis. We identified several novel pathways responsible for the protective effects of β-escin on the vascular endothelium under inflammatory conditions.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/30377 must be provided.

1. Endothelial P2Y receptors as novel targets for a pharmacological intervention
2. In the quest for a new endothelium-protecting drug among escin derivatives